Tag:
Horizant
Latest Headlines
Latest Headlines
GSK hits back at XenoPort in RLS drug dispute
XenoPort knew it would get GlaxoSmithKline's ( $GSK ) attention with a termination notice. But the sort of attention it wanted? Probably not the sort it got.
GSK asks FDA for new nod on restless legs drug
Fresh off an approval for restless leg syndrome in April, GlaxoSmithKline ( $GSK ) has asked the FDA to bless Horizant for use against shingles pain. A long-lasting version of the seizure drug
GSK readies 500 reps for Horizant launch
Now that they have FDA approval for Horizant in the bag, GlaxoSmithKline and Xenoport are working out a sales strategy. And if the companies' statistics hold true, there are more than 5 million
XenoPort rockets up after FDA approves Horizant for RLS
After surviving a turbulent year marked by a painful restructuring and a setback in the clinical development of one of its key programs, XenoPort ( $XNPT ) has won approval for Horizant, a new therapy
GSK, XenoPort revise Horizant pact
Just a few days after the FDA accepted GlaxoSmithKline's ( $GSK ) response to its complete response letter on Horizant for review, XenoPort ( $XNPT ) announced that it had revised its development pact
XenoPort's lead program suffers another big setback
A bad year for XenoPort ( XNPT ) just got substantially worse. The Santa Clara, CA-based developer says that its lead program--which is partnered with GlaxoSmithKline--flunked a Phase IIb trial for
FDA wants preclinical data on XenoPort's Horizant
Shares of XenoPort were buoyed by the news that regulators had asked for preclinical data on its experimental therapy for restless leg syndrome but were not asking for any new trials. XenoPort plans
XenoPort cuts 50% of workforce
In a terse announcement released Friday, Santa Clara, CA-based XenoPort said it's cutting 50 percent of its 219-person staff and refocusing its development efforts on its late-stage product
XenoPort meltdown triggers collateral damage at Depomed
The FDA's decision to reject a marketing application for a new restless leg syndrome therapy from XenoPort and GlaxoSmithKline triggered a 66 percent plunge in the smaller developer's share price
